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Abstract
Aim: To review evidence concerning the oncological safety of performing skin-sparing mastectomy
(SSM) for invasive breast cancer and ductal carcinoma in situ (DCIS). Furthermore, the evidence
concerning RT in relation to SSM and the possibility of nipple preservation was considered.
Methods: Literature review facilitated by Medline and PubMed databases.
Findings:  Despite the lack of randomised controlled trials, SSM has become an accepted
procedure in women undergoing mastectomy and immediate reconstruction for early breast
cancer. Compared to non-skin-sparing mastectomy (NSSM), SSM seems to be oncologically safe in
patients undergoing mastectomy for invasive tumours smaller than 5 cm, multicentric tumours,
DCIS or risk-reduction. However, the technique should be avoided in patients with inflammatory
breast cancer or in those with extensive tumour involvement of the skin in view of the high risk of
local recurrence. SSM with nipple areola complex (NAC) preservation appears to be oncologically
safe, provided the tumour is not close to the nipple and a frozen section protocol for the retro-
areolar tissue is followed. Although radiotherapy (RT) does not represent a contraindication to
SSM, the latter should be used with caution if postoperative RT is likely, since it detracts from the
final cosmetic outcome.
Background
Immediate or delayed breast reconstruction following
conventional non-skin sparing mastectomy (NSSM) often
results in prominent scars on the new breast and a paddle
of skin that is of a different colour and texture. Skin-spar-
ing mastectomy (SSM) preserves most of the overlying
skin (figures 1 and 2) during an immediate breast recon-
struction (IBR) thus leading to a superior aesthetic out-
come (figures 2 and 3). It also reduces the need for
contralateral breast adjustment in order to achieve sym-
metry [1]. In a recent survey in the UK, 35 out of 95 breast
surgeons avoided SSM because of concerns over oncolog-
ical safety or uncertainty of the benefits or indications [2].
In view of these uncertainties, this article reviews the con-
troversies surrounding SSM, using Medline and PubMed
databases and the keywords 'skin-sparing mastectomy',
'subcutaneous mastectomy' and 'immediate breast recon-
struction'.
Oncological concerns
The main oncological concern in both SSM and NSSM
relates to the possibility of leaving residual tumour within
the skin envelope which may manifest later as local recur-
rence (LR). Indeed, Ho et al [3] performed histological
examinations of the skin and subcutaneous tissue of 30
NSSM specimens and found that the skin flaps (excluding
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the NAC) were involved in 23% (7 of 30) of cases. In 5
cases, the skin involved was situated directly over the
tumour. Unfortunately, many of the studies addressing
the issue of LR following SSM have not followed-up
patients long enough for it to be seen. In addition, there is
a significant lack of prospective data and nearly all studies
are from single institutions. However, the incidence of LR
following SSM for invasive breast cancer has been retro-
spectively investigated by several authors and is summa-
rised in table 1[4-15]. The largest series [5] observed 539
patients over a period of 65 months. 30.6% of cases had
non-invasive disease. The LR rate was 5.5%. Furthermore,
LR was related to tumour size, grade, nodal status and
lymphovascular invasion. LR rates were similar for T2 and
T3 tumours, although this does not correlate with the lab-
oratory observations of Ho et al [3]. Other studies have
found even lower LR rates. A study of 176 breast cancers
treated by SSM and IBR reported a LR rate of 4.5% after a
median follow-up of 73 months [6]. After 9.8 years' fol-
low-up of 177 SSMs, Spiegel and Butler [7] reported a LR
rate of 5.6%. In a series of only T1 and T2 breast cancers,
a LR of 6.2% for 372 SSMs (23/372) was reported after
only 26 months' follow-up [8]. Similarly, Kroll observed
a 7.0% LR rate (8/114 cases) in patients with T1/T2
tumours treated by this method [9]. In addition, they
found a similar LR rate of 7.5% (3/40) in women treated
by NSSM and IBR. One study found no LRs in a series of
50 patients after a follow up of 51 months, although there
were 5 distant recurrences [4]. Many of these studies
found that tumour size, stage, lymph node positivity and
poor differentiation were all risk factors for LR. Unfortu-
nately, the frequency of giving radiotherapy (RT) and
chemotherapy was not uniform across these series which
may explain the variable LR rates.
In a large series of standard mastectomies and wide local
excisions by Fisher, the LR rate of breast cancer after NSSM
in tumours up to 4 cm was found to be 10% after 20 years
follow-up [16]. This approximately equates to 0.5% per
year. The studies outlined above have demonstrated that
the average LR rate following SSM and IBR is similar to
that reported for NSSM, although the period of follow-up
duration for SSM is shorter.
Unfortunately, it is unlikely that large multi-centre ran-
domised studies comparing NSSM and SSM will take
place. However, although the above studies are retrospec-
tive and relatively small, there is reasonable evidence that
SSM is a safe oncological operation for T1, T2 and multi-
centric tumours. Moreover, there is evidence that SSM
combined with IBR does not significantly delay adjuvant
therapy, as some clinicians had feared [17]. Many T1/T2
tumours, however, can be treated adequately by breast
conservation surgery followed by RT [16,18] which may
be preferred to IBR if cosmesis is a high priority. Many
patients requiring mastectomy have T3 tumours, yet the
evidence for the safety of SSM for these tumours is less
clear, but encouraging. In a study of 38 patients with
tumours considered to be at high risk of LR, only one case
(2.6%) developed a LR after SSM and IBR after 53 months
of follow-up, despite 10 (26%) systemic recurrences [15].
Yet a further option for patients with T3 tumours is to
administer neoadjuvant chemotherapy in an attempt to
shrink the tumour. If shrinkage does occur, it may facili-
tate performance of SSM in a breast which may otherwise
have required a NSSM. Alternatively, it may even facilitate
breast conservation surgery, avoiding the need for a mas-
tectomy altogether.
Surgical considerations
Although the incision(s) differ, the technique of dissect-
ing the skin flaps during SSM is similar to that of NSSM.
Native skin flap necrosis (partial or complete) has been
estimated to occur in 11% of cases and is similar in SSM
and NSSM [19]. Since the main difference between SSM
and NSSM is that the standard incision for SSM is circu-
mareolar rather than a large ellipse [20,21], the only
The peri-areola incision of standard skin-sparing mastectomy Figure 1
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breast skin excised is the nipple areola complex (NAC)
(see figure 1 and 2). SSM combined with sentinel node
biopsy (SNB) and/or axillary node clearance (ANC) can
be safely performed through this incision [1,21], although
some prefer to perform the axillary procedure through a
separate small incision in the axilla [22]. The latter is hid-
den from view, maintaining cosmesis. Some surgeons per-
form an intra-operative histopathological assessment of
the sentinel node (frozen section or imprint cytology) and
perform an immediate ANC if the SNB is positive for
malignancy. An alternative approach is to perform a day-
case sentinel node biopsy one or two weeks before the
mastectomy so that nodal status is known. Additionally,
to maximise a good cosmetic outcome, the dissection of
the lower skin flap should not continue beyond the
inframammary fold, so that the final shape of the recon-
struction will be very similar to the original breast [23]. In
patients with large ptotic breasts, SSM can be performed
through the standard incisions used for reduction mam-
moplasty [24]. Symmetry may be achieved by performing
a simultaneous, or delayed, contralateral reduction mam-
moplasty using similar incisions.
SSM for DCIS
A standard mastectomy (NSSM) for DCIS achieves cure
rates of approximately 98% (LR rate of 1.4% and breast
cancer-specific mortality of 0.59%) [25]. Furthermore, RT
is not usually required afterwards. Consequently, SSM
and IBR would appear to be an ideal choice for women
undergoing mastectomy and reconstruction for DCIS,
since postoperative RT side-effects are no longer a con-
cern. In one series [26], 93 out of 95 patients (98%) who
had undergone SSM and IBR for DCIS were alive and dis-
ease-free after 3.7 years of follow-up. In 35 cases, the mar-
gins were closely examined by performing intra-operative
specimen radiography and histological examination of
serial sections. Margins were found to be negative in 77%
of the cases. In the remainder, further tissue was removed.
None of these 35 cases developed LR. 3 of the 58 other
cases developed LR. The overall LR rate was, therefore, 3
out of 93 (3%). A larger series by Carlson et al. included
175 cases of DCIS5 in which there was only one LR
(0.6%) after 65 month' follow-up. None of 26 DCIS
patients developed LR in the study by Slavin et al. after 45
months [10]. Finally, in a longer-term follow-up retro-
spective study of 44 patients who underwent SSM and IBR
for DCIS, there were no local or distant recurrences by 9.8
years [7]. These retrospective studies have all demon-
strated that SSM and IBR for DCIS is oncologically safe
with low recurrence rates (see table 2). However, prospec-
tive data to confirm these findings is not available.
A: This 40 year old woman had left SSM and immediate LD  flap reconstruction for DCIS last year Figure 2
A: This 40 year old woman had left SSM and immediate LD 
flap reconstruction for DCIS last year. She is due to have nip-
ple reconstruction shortly. B, C, and D: This 52 year old 
woman had right SSM and LD flap reconstruction followed 
by nipple reconstruction using a local skin flap (Trefoil tech-
nique) and subsequent tattooing 3 years ago.
A
C
D B
Table 1: Oncological safety of skin-sparing mastectomy for invasive breast cancer – summary of recent studies.
Authors Year Sample size L.R. (%) F/U (months) Notes
Slavin et al10 1998 51 2.0 45 26 DCIS cases.
Newman et al8 1998 372 6.2 26 T1/T2 tumours.
Simmons et al13 1999 77 3.9 60
Toth et al4 1999 50 0 51.5
Kroll et al9 1999 114 7.0 72 T1/T2 tumours.
Rivadeneira et al12 2000 71 5.1 49
Foster et al11 2002 25 4.0 49 Locally advanced.
Medina-Franco et al6 2002 176 4.5 73
Spiegel and Butler7 2003 177 5.6 118
Carlson et al5 2003 539 5.5 65 30.6% DCIS.
Gerber et al14 2003 112 5.4 59
Downes et al15 2005 38 2.6 53 'High risk tumours'
Abbreviations: L.R. = local recurrence; F/U = follow-up interval.International Seminars in Surgical Oncology 2006, 3:14 http://www.issoonline.com/content/3/1/14
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The oncological safety of nipple areola complex 
preservation
Although IBR following SSM may offer cosmetic benefits
over NSSM, removal of the nipple areola complex (NAC)
significantly impacts on the final outcome. Patients are
offered a subsequent delayed nipple reconstruction and
areola tattooing or a prosthetic NAC. The NAC is removed
because of the belief that the NAC and its adjacent ducts
may contain tumour cells which have spread distally
along the ducts from the primary tumour. This concept
was based on older studies that had demonstrated occult
tumour in the region of the NAC [23]. Recent evidence
has shown that the risk of tumour involvement of the
NAC has been overestimated [27-29]. This has led some
surgeons to attempt preservation of the NAC in view of
the cosmetic benefit. In a retrospective series of 286 SSM
specimens, 16 (5.6%) were found to contain tumour in
the NAC [27]. Nodal positivity, subareolar tumour loca-
tion and multicentricity were significant risk factors for
NAC involvement. If multicentric and subareolar tumours
were excluded, the NAC was only involved in 3% of cases.
Another series of 140 mastectomies also found tumour
size and nodal positivity to be risk factors for NAC
involvement [28]. Furthermore, the primary tumour was
situated within 2.5 cm of the areola in all 22 cases in
which the NAC was positive. A retrospective study involv-
ing 217 mastectomy specimens by Simmons et al.
reported NAC tumour involvement in 23 cases (10.6%)
[29]. It was also found that only 6.7% of small tumours
with up to two positive lymph nodes only had NAC
involvement. In contrast to these modest figures, one
report found that the NAC was involved in up to 58% of
mastectomy specimens [30]. Reasons for this difference
are unclear, although this is the only study to publish such
a high probability of NAC involvement. More recently,
Gerber et al. performed 112 SSMs in women whose breast
cancer was more than 2 cm from the NAC [14]. Histolog-
ical examination of intra-operative frozen sections of the
subareolar tissue was performed in an attempt to predict
NAC involvement. The biopsies were negative for tumour
in 61 (54.5%) cases, thus enabling NAC preservation. The
NAC was excised in the other 51 cases. The cosmetic
results after SSM and IBR (using LD or TRAM flaps) were
independently evaluated as excellent or good in 91%
(102/112) of patients and were significantly better after
preservation of the NAC (P = 0.001). Six (5.4%) recur-
rences occurred in 112 patients who underwent SSM com-
pared with 11 (8.2%) of 134 patients who had undergone
NSSM during the same 6-year period. Only one LR
occurred in the NAC preservation group. Therefore, it
would appear oncologically safe to perform SSM with
NAC preservation, provided the tumour is not close to the
nipple and a frozen section protocol is followed. Unfortu-
nately, up to one-third of patients lose part or all of the
NAC after this operation due to impaired NAC blood sup-
ply [31], although Crowe et al [32] found this complica-
tion to be relatively uncommon. Differences are likely to
be due to surgical technique. In the latter study, 54 SSMs
in 44 patients were performed in which the NAC was clin-
ically thought to be disease-free. Nipple core biopsy fro-
zen sections were performed. 6 out of 54 biopsies were
positive, necessitating conversion to conventional SSM.
Of the remaining 48 NAC-sparing SSMs, 45 had no skin
loss and only the remaining 3 cases had partial NAC loss.
In a different series of 54 SSMs of which 34 had NAC pres-
ervation [33], the skin loss was higher in the latter group
although LR was similar (8.3% when NAC excised; 7.1%
when NAC preserved).
An alternative to NAC-sparing SSM is to remove the nip-
ple but preserve the areola – a technique called areola-
sparing mastectomy (ASM). The concept of this technique
is supported by the findings of Simmons et al. who found
This 42 year old doctor had left skin-sparing mastectomy and  immediate breast reconstruction using the latissimus dorsi  myocutaneous flap and implant 2 years ago, followed by a  nipple reconstruction using the nipple-sharing technique and  tattooing Figure 3
This 42 year old doctor had left skin-sparing mastectomy and 
immediate breast reconstruction using the latissimus dorsi 
myocutaneous flap and implant 2 years ago, followed by a 
nipple reconstruction using the nipple-sharing technique and 
tattooing.International Seminars in Surgical Oncology 2006, 3:14 http://www.issoonline.com/content/3/1/14
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that the areola itself was only involved in 2 of the 23 cases
of positive NACs [29]. This represented 0.9% of all the
mastectomy specimens. Access for ASM is facilitated by
medial and lateral extensions to the incision encircling the
nipple. This may achieve a superior cosmetic outcome
compared to conventional SSM, only requiring a subse-
quent nipple reconstruction, if requested by the patient.
Unfortunately, nipple reconstruction using one of the
conventional local flap technique is problematic in this
situation. The only published series of areola-sparing SSM
was also by Simmons [34] who reported 17 cases with
only a single complication (wound infection) over a 20-
month period.
RT after SSM
Most women undergoing mastectomy for breast cancer do
not require post-operative RT. However, patients with sev-
eral positive regional lymph nodes and/or large tumours
are offered RT in view of the proven reduction in loco-
regional recurrence and improved survival [35]. Similarly,
RT is also indicated in some patients who have undergone
SSM and IBR. Recently, the incidence of post-mastectomy
RT has been increasing [36]. Post-reconstruction RT is
unfortunately associated with local complications, thus
causing some debate as to the safety of performing SSM
and IBR in women who are likely to require this treat-
ment. There is a lack of prospective trials concerning the
use of RT with SSM and most of the published evidence is
derived by enthusiasts from single-centres.
Although results from individual series vary considerably,
it appears that the complications of RT following immedi-
ate breast reconstruction occur in a high proportion of
patients [37]. A study of immediate TRAM reconstructions
showed the commonest complications were fat necrosis
(16%) and radiation fibrosis (11%) [38], although this
population underwent autologous reconstructions. Fat
necrosis leads to volume loss and hardening of the recon-
structed breast and particularly occurs when RT is given
after IBR using free tissue transfer of skin and fat only (e.g.
deep inferior epi-gastric perforator; DIEP flap). The main
concern regarding RT in the reconstructed breast, how-
ever, is related to the use of implants, either alone or in
conjunction with a flap reconstruction. The fibrosis in
particular often causes subsequent shrinkage of the recon-
structed breast around the implant – termed 'capsular
contraction'. One study compared 39 irradiated implant
reconstructed breasts with 338 non-irradiated reconstruc-
tions and found a significant negative effect on the recon-
structive outcome with implants [39], the main
complications being capsular contracture and post-opera-
tive pain. 43% of patients underwent a subsequent cap-
sulotomy. Capsular contraction results in poor aesthetic
outcomes in many cases, sometimes even requiring fur-
ther flap surgery. This has led some surgeons to recom-
mend that IBR using implants, including SSM, be avoided
if it is known that a patient is likely to require postopera-
tive RT [37]. Alternative approaches are to either use an
autologous IBR, to deliberately oversize the reconstruc-
tion, or to place a temporary tissue expander under the
SSM skin envelope deep to the pectoralis major muscle –
following RT, the delayed reconstruction can be per-
formed using a myocutaneous flap and implant after
removing the tissue expander [23]. Other surgeons do not
hold this view. In another retrospective study [40], 68
IBRs who received postoperative RT were compared with
75 IBRs who did not. It was found that although capsular
contracture rates (68% v 40%, respectively), cosmetic out-
come (good or better in 80% v 88%) and patient satisfac-
tion (67% v 88%) all favoured the group who avoided RT,
72% of those irradiated said that they would still chose
the same form of reconstruction again.
Hultman and Daiza investigated the effects of previous RT
on subsequent SSM and IBR in 37 breasts, although not
all patients had received previous RT [41]. TRAM and LD
flaps and implant reconstructions were all included. 9
patients (24%) had a SSM flap complication of which 5
required re-operations. Previous irradiation and diabetes
were found to be significant risk factors for complications.
The issue of pre-operative RT and SSM was also investi-
gated by Disa et al [42]. Their study included only 11
patients who underwent SSM and IBR after developing
LRs following previous breast conservation surgery and
RT. They observed that all the flaps survived, one patient
developed partial thickness skin flap loss and two devel-
oped capsular contractures, leading them to conclude that
SSM and IBR can be safely performed in previously irradi-
ated breasts. Furthermore, Benediktsson and Perbeck have
shown that RT does not significantly compromise the skin
Table 2: Outcome of skin sparing mastectomy for DCIS – summary of recent studies.
Authors Year Sample size L.R. (%) Follow-up
Slavin et al10 1998 26 0 45 months
Rubio et al26 2000 95 3 3.7 years
Spiegel & Butler7 2003 44 0 9.8 years
Carlson et al5 2003 175 0.6 65 months
Abbreviations: L.R. = local recurrenceInternational Seminars in Surgical Oncology 2006, 3:14 http://www.issoonline.com/content/3/1/14
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circulation of the breast [43]. Therefore, as long as a
slightly higher complication rate is accepted and the
patients are fully informed, it would appear safe for
women to undergo SSM and IBR after previous breast RT.
However, these studies are small and larger studies with
longer follow-up are required to verify these findings.
Abbreviations
skin-sparing mastectomy (SSM); ductal carcinoma in situ
(DCIS); immediate breast reconstruction (IBR); non-skin-
sparing mastectomy (NSSM); nipple areola complex
(NAC); areola-sparing mastectomy (ASM); radiotherapy
(RT); local recurrence (LR)
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